Deloitte buys data warehouse firm

| | Health Exec | Economics

Deloitte Consulting Services has acquired Recombinant Data, a developer of data warehousing and clinical intelligence systems for personalized medicine, translational research and healthcare performance management. Terms of the acquisition were not disclosed.

Based in Newton, Mass., Recombinant, founded in 2005, seeks to relate to enterprise data integration, population health analytics, clinical genome data assimilation and performance management for accountable care organizations. According to Deloitte, Recombinant also seeks to assist academic medical centers, federal agencies and life sciences companies conduct translational research and analyze phenomic, genomic and bio-banking data in pursing personalized and evidence-based medicine.

Recombinant’s business will reside within Deloitte Consulting Innovation under the name “Recombinant By Deloitte.”

 

 

Related Content

Bill to regulate healthcare private equity lands on desk of Mass. governor
Mayo Clinic sues insurer over $740K in medical bills for patient
The biggest challenges facing radiology business managers in 2025
Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.